Crohn's Disease clinical trials
136 active trials name this condition (recorded in the registry as “Crohn Disease”) . Describe your situation to see which ones you may be eligible for.
By location
- A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
- DB-3Q bmMSC-EVs in Patients With Perianal Fistulizing Crohn's Disease
- A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
- Ultrasound-Guided Versus Standard Margin Selection in Ileocecal Resection of Terminal Ileal CD
- A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Amitriptyline for IBS-like Symptoms in Quiescent Crohn's Disease
- A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
- A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
- Comparing Over the Counter Pain Medicines for Discomfort in Crohn's Disease (AVID-CD)
- A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
- A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease
- Stem Cell Transplantation in Crohn's Disease
- Treatment of Moderate to Severe Refractory Crohn's Disease
- A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
- Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
- An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
- A Pilot Study Examining Low Sulfur Diet as Treatment for Persistent Symptoms in Quiescent Crohn's Disease
- VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
- Autologous Stem Cell Transplantation for Crohn's Disease
- Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
- Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
- A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
- Behavioral Therapy for Crohn's Disease
- A Pilot Study to Assess the Safety, Tolerability, and Efficacy of Virtual Reality for the Treatment of Abdominal Pain in Quiescent Crohn's Disease
- A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
- Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
- Precise Infliximab Exposure and Pharmacodynamic Control
- Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
- A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
- A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.
- A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
- A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
- A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
- A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
- Reverse-Engineering of Exclusive Enteral Nutrition (RE-EEN) in Crohn's Disease: A Multi-Center Trial
- A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting
- Low Dose IL-2 for the Treatment of Crohn's Disease
- A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
- A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
- Autologous Stem Cell Transplant for Crohn's Disease
- Effect of Mediterranean Diet in Inflammatory Bowel Disease
- A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- HB-adMSCs for the Treatment of Crohn's Disease
- A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Crohn Disease” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.